MedTrace Logo

Misoprostol for NASH

NCT05804305 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-04-07

No results posted yet for this study

Summary

The aim of this randomised control trial is to evaluate the effect of Misoprostol in treating patients with NASH.

Conditions

  • NASH

Interventions

DRUG

Misoprostol

Misoprostol is a prostaglandin E1 analogue

DRUG

Placebo

Placebo contained substance that has no therapeutic value.

Sponsors & Collaborators

  • Nabiqasim Industries (Pvt) Ltd

    collaborator INDUSTRY

  • Ziauddin University

    lead OTHER

Principal Investigators

  • Mehreen Siyal, MBBS, FCPS-1 · Dr. Ziauddin Hospital Clifton

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05804305 on ClinicalTrials.gov